Lenalidomide Polarizes Th1-specific Anti-tumor Immune Response and Expands XBP1 Antigen-Specific Central Memory CD3(+)CD8(+) T cells against Various Solid Tumors

INTRODUCTION: Effective combination immunotherapeutic strategies may be required to enhance effector cells’ anti-tumor activities and improve clinical outcomes. METHODS: XBP1 antigen-specific cytotoxic T lymphocytes (XBP1-CTL) generated using immunogenic heteroclitic XBP1 US184-192 (YISPWILAV) and X...

Descripción completa

Detalles Bibliográficos
Autores principales: Bae, Jooeun, Keskin, Derin B, Cowens, Kristen, Lee, Ann-Hwee, Dranoff, Glen, Munshi, Nikhil C, Anderson, Kenneth C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2015
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5032910/
https://www.ncbi.nlm.nih.gov/pubmed/27668268
http://dx.doi.org/10.4172/2329-6917.1000178

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5032910/
https://www.ncbi.nlm.nih.gov/pubmed/27668268
http://dx.doi.org/10.4172/2329-6917.1000178

Ejemplares similares